Text Size

Forced Diuresis Versus Observation in Resolving Renal Failure After Haemofiltration in Critically Ill Patients

This study has been terminated.
(Number included has been reached)
Sponsor:
Information provided by:
Medical Centre Leeuwarden
ClinicalTrials.gov Identifier:
NCT00298454
First received: March 1, 2006
Last updated: April 18, 2007
Last verified: April 2007
History of Changes
  Purpose

Intensive care patients with multiple organ dysfunction syndrome often show renal failure with the need for hemofiltration. Resolving renal failure after cessation of hemofiltration may or may not be accompanied by oliguria. Whether or not the administration of diuretics at that moment is appropriate is not known. The study randomises between furosemide or placebo when hemofiltration is stopped. Study endpoint is recovery of renal function.


Condition Intervention Phase
Renal Failure
Critically Ill
 Drug: Furosemide
 Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: Forced Diuresis Vs Observation in Resolving Renal Failure After Haemofiltration in Critically Ill Patients (Fodorefh)

Resource links provided by NLM:

Drug Information available for: Furosemide
U.S. FDA Resources

Further study details as provided by Medical Centre Leeuwarden:

Primary Outcome Measures:
  • Creatinin clearance

Secondary Outcome Measures:
  • length of stay in the intensive care and hospital
  • intensive care and hospital mortality

Estimated Enrollment: 72
Study Start Date: December 2005
Study Completion Date: April 2007
  Show Detailed Description

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • cessation of hemofiltration
  • mechanical ventilation
  • written informed consent

Exclusion Criteria:

  • pre-existent renal failure
  • glomerulonephritis
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00298454

Locations
Netherlands
Dept of intensive care, Medical Centre Leeuwarden
Leeuwarden, Fr, Netherlands, 8901 BR
Sponsors and Collaborators
Medical Centre Leeuwarden
Investigators
Principal Investigator: Peter van der Voort, MD, PhD, MSc Dept of intensive care, Medical Centre Leeuwarden, PO Box 888,8901BR Leeuwarden, The Netherlands
  More Information

No publications provided by Medical Centre Leeuwarden

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

ClinicalTrials.gov Identifier: NCT00298454     History of Changes
Other Study ID Numbers: 200601
Study First Received: March 1, 2006
Last Updated: April 18, 2007
Health Authority: Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)

Keywords provided by Medical Centre Leeuwarden:
renal failure
oliguric
critically ill
furosemide

Additional relevant MeSH terms:
Critical Illness
Renal Insufficiency
Disease Attributes
Pathologic Processes
Kidney Diseases
Urologic Diseases
Furosemide
Sodium Potassium Chloride Symporter Inhibitors
 Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Diuretics
Natriuretic Agents
Physiological Effects of Drugs
Cardiovascular Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on May 23, 2013